changes in protein profiles in bortezomib applied multiple myeloma ...
changes in protein profiles in bortezomib applied multiple myeloma ...
changes in protein profiles in bortezomib applied multiple myeloma ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
1.2.7. Treatment Strategy for MM<br />
1.2.7.1. Bortezomib<br />
Treatment strategy for MM is a very important and vital step for the patients,<br />
because MM is currently still an <strong>in</strong>curable disease (Pandit, 2005; Dmoszyńska, 2008).<br />
Bortezomib (Velcade ® , Millennium Pharmaceuticals Inc., and Johnson & Johnson<br />
Pharmaceutical Research & Development, LLC) (LCLabs, USA) is the first of a new<br />
class of anti-cancer agents known as proteasome <strong>in</strong>hibitor that was entered cl<strong>in</strong>ical<br />
trials and firstly confirmed by the US Food and Drug Adm<strong>in</strong>istration (FDA) and the<br />
European Agency for the Evaluation of Medic<strong>in</strong>al Products (EMEA) for the treatment<br />
of MM (Mateos and Miguel, 2007).<br />
Bortezomib (previously known as PS-341, LDP-341, MLN341) is a dipeptide<br />
boronic acid derivative, which specifically and reversibly <strong>in</strong>hibit proteasome activity<br />
and triggers apoptosis <strong>in</strong> MM by b<strong>in</strong>d<strong>in</strong>g the catalytic site of the 26S proteasome with<br />
high aff<strong>in</strong>ity and specificity with the boron atom <strong>in</strong> its structure (Elliott and Ross, 2001;<br />
Blade et al., 2003; Richardson et al., 2003; Voorhees et al., 2003; Adams and<br />
Kauffman,2004; Chauhan et al., 2005). The chemical formula and molecular weight of<br />
Bortezomib is C19H25BN4O4 and 384.24 g / mol respectively. The chemical structure of<br />
Bortezomib is as follows (Figure 1.7).<br />
Figure 1.7. Structure of Bortezomib<br />
(Source: Blade et al., 2005)<br />
19